I agree that this site is using cookies. You can find further informations here.
X
Park, Keunchil
577  results:
Online X
Search for persons X
?
1

Biomarker-directed targeted therapy plus durvalumab in adva..:

Besse, Benjamin ; Pons-Tostivint, Elvire ; Park, Keunchil...
Nature Medicine.  30 (2024)  3 - p. 716-729 , 2024
Link: https://doi.org/10.1038/..
 
?
2

A brief report on stable disease among amivantamab-treated ..:

Girard, Nicolas ; Park, Keunchil ; Lee, Se-Hoon...
Cancer Treatment and Research Communications.  40 (2024)  - p. 100832 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Comprehensive analysis of transcription factor-based molecu..:

Park, Sehhoon ; Hong, Tae Hee ; Hwang, Soohyun...
eBioMedicine.  102 (2024)  - p. 105062 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Avelumab Versus Platinum-Based Doublet Chemotherapy as Firs..:

Reck, Martin ; Barlesi, Fabrice ; Yang, James Chih-Hsin...
Journal of Thoracic Oncology.  19 (2024)  2 - p. 297-313 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Real-World Efficacy and Safety of Amivantamab for EGFR-Muta..:

Wang, Kaiwen ; Du, Robyn ; Myall, Nathaniel J....
Journal of Thoracic Oncology.  19 (2024)  3 - p. 500-506 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Plain language summary of PAPILLON: amivantamab plus chemot..:

Sabari, Joshua K ; Girard, Nicolas ; Mansfield, Aaron S...
Future Oncology.  , 2024
Link: https://doi.org/10.1080/..
 
?
7

Management of infusion-related reactions (IRRs) in patients..:

Park, Keunchil ; Sabari, Joshua K. ; Haura, Eric B....
Lung Cancer.  178 (2023)  - p. 166-171 , 2023
Link: https://doi.org/10.1016/..
 
?
8

A Phase 2 Study of Palbociclib for Recurrent or Refractory ..:

Jung, Hyun Ae ; Kim, Miso ; Kim, Hae Su...
Journal of Thoracic Oncology.  18 (2023)  2 - p. 223-231 , 2023
Link: https://doi.org/10.1016/..
 
?
9

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Tre..:

Kim, Dong-Wan ; Kim, Sang-We ; Camidge, D. Ross...
Journal of Thoracic Oncology.  18 (2023)  5 - p. 650-656 , 2023
Link: https://doi.org/10.1016/..
 
?
10

A plain language summary of the results from the group of p..:

Spira, Alexander ; Girard, Nicolas ; Krebs, Matthew...
Future Oncology.  19 (2023)  33 - p. 2213-2225 , 2023
Link: https://doi.org/10.2217/..
 
?
11

Whole-Section Landscape Analysis of Molecular Subtypes in C..:

Hwang, Soohyun ; Hong, Tae Hee ; Kim, Hong Kwan...
Modern Pathology.  36 (2023)  7 - p. 100184 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Biomarker‐driven phase 2 umbrella trial: Clinical efficacy ..:

Park, Sehhoon ; Kim, Yu Jung ; Min, Young Joo...
Cancer.  130 (2023)  4 - p. 541-552 , 2023
Link: https://doi.org/10.1002/..
 
?
13

Efficacy and Safety of Ceritinib 450 mg/day with Food and 7..:

Cho, Byoung Chul ; Kim, Dong-Wan ; Batra, Ullas...
Cancer Research and Treatment.  55 (2023)  1 - p. 83-93 , 2023
Link: https://doi.org/10.4143/..
 
?
14

Expanded Access Program Pralsetinib in Advanced Non–Small C..:

Jeon, Youngkyung ; Jung, Hyun Ae ; Park, Sehhoon...
Cancer Research and Treatment.  55 (2023)  4 - p. 1144-1151 , 2023
Link: https://doi.org/10.4143/..
 
?
15

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mu..:

Cho, Byoung Chul ; Kim, Dong-Wan ; Spira, Alexander I....
Nature Medicine.  29 (2023)  10 - p. 2577-2585 , 2023
Link: https://doi.org/10.1038/..
 
1-15